Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Recommendation of “Hold” by Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has received a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $2.32.

Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a report on Friday, November 29th. They set a “sell” rating on the stock.

Cara Therapeutics Price Performance

Shares of NASDAQ:CARA opened at $0.27 on Thursday. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31. The company has a market capitalization of $15.03 million, a P/E ratio of -0.16 and a beta of 0.64. The firm’s 50 day simple moving average is $0.29 and its two-hundred day simple moving average is $0.36.

Institutional Investors Weigh In On Cara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Disciplined Growth Investors Inc. MN increased its position in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the last quarter. FMR LLC boosted its stake in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Cara Therapeutics in the third quarter worth about $29,000. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.